← Back to Search

Dual-Energy CT Scan for Carcinoid Tumors

Q: Are there any vacancies in this clinical experiment for participants?

<p>Yes, the information available on clinicaltrials.gov confirms that this therapeutic research is presently recruiting subjects. The trial was initially published on September 23rd 2015 with its most recent update occurring February 24th 2023. This study seeks 66 participants from a single site of recruitment.</p>

Q: What is the total participant count for this clinical research?

<p>Affirmative. As documented by clinicaltrials.gov, this medication trial is presently recruiting participants that meet the criteria for inclusion. The initial call for enrolment was made on September 23rd 2015 and the latest edit to the listing occurred February 24th 2023; 66 individuals are necessary from a single medical centre.</p>

Phase < 1

Recruiting

Led By Ajaykumar Morani

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with endoscopic biopsy proven carcinoid

Patients with increased serum and urinary markers suggestive of carcinoid

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

Study Summary

This trial looks at using a special CT scan to detect gastrointestinal carcinoid tumors. The scan uses x-rays and a computer to create images of inside the body.

Who is the study for?

This trial is for individuals with signs of carcinoid syndrome, increased markers indicating carcinoid, confirmed diagnosis through biopsy, or metastases known to be from a carcinoid tumor. They must be scheduled for a CT scan and have consented to participate. Pregnant individuals or those allergic to contrast agents used in scans cannot join.Check my eligibility

What is being tested?

The study is examining the effectiveness of Dual Energy Computed Tomography (DECT) in detecting gastrointestinal carcinoid tumors during routine CT scans. Researchers aim to determine if DECT can enhance the imaging and identification of these tumors.See study design

What are the potential side effects?

While there are no direct side effects from the dual energy CT itself being tested, participants may experience reactions related to the use of intravenous contrast agents such as allergic reactions or kidney issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My biopsy confirmed I have carcinoid cancer.

Select...

My tests show markers indicating I might have carcinoid cancer.

Select...

My cancer spread is confirmed as carcinoid through a biopsy.

Select...

I show symptoms of carcinoid syndrome.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Sensitivity and specificity of dual energy computed tomography in detecting primary gastrointestinal carcinoid tumors

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic (dual energy CT scan)Experimental Treatment1 Intervention

Patients undergo one dual energy CT scan during scheduled CT scan.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Dual-Energy Computed Tomography

2018

N/A

~50

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,974 Previous Clinical Trials

1,789,408 Total Patients Enrolled

5 Trials studying Carcinoid Tumor

210 Patients Enrolled for Carcinoid Tumor

Ajaykumar MoraniPrincipal InvestigatorM.D. Anderson Cancer Center

Vikas KundraPrincipal InvestigatorM.D. Anderson Cancer Center

5 Previous Clinical Trials

352 Total Patients Enrolled

Media Library

Dual-Energy Computed Tomography Clinical Trial Eligibility Overview. Trial Name: NCT04993261 — Phase < 1

Carcinoid Tumor Research Study Groups: Diagnostic (dual energy CT scan)

Carcinoid Tumor Clinical Trial 2023: Dual-Energy Computed Tomography Highlights & Side Effects. Trial Name: NCT04993261 — Phase < 1

Dual-Energy Computed Tomography 2023 Treatment Timeline for Medical Study. Trial Name: NCT04993261 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies in this clinical experiment for participants?

"Yes, the information available on clinicaltrials.gov confirms that this therapeutic research is presently recruiting subjects. The trial was initially published on September 23rd 2015 with its most recent update occurring February 24th 2023. This study seeks 66 participants from a single site of recruitment."

Answered by AI

What is the total participant count for this clinical research?

"Affirmative. As documented by clinicaltrials.gov, this medication trial is presently recruiting participants that meet the criteria for inclusion. The initial call for enrolment was made on September 23rd 2015 and the latest edit to the listing occurred February 24th 2023; 66 individuals are necessary from a single medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

2015. "An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04993261.

All > Carcinoid Tumor